Overview

Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group

Status:
Completed
Trial end date:
2013-07-31
Target enrollment:
Participant gender:
Summary
A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease
Phase:
Phase 3
Details
Lead Sponsor:
Hanlim Pharm. Co., Ltd.
Treatments:
Cyclosporine
Cyclosporins
Ophthalmic Solutions
Tetrahydrozoline